Product Description
Indomethacin is used to relieve moderate to severe pain, tenderness, swelling, and stiffness caused by osteoarthritis (arthritis caused by a breakdown of the lining of the joints), rheumatoid arthritis (arthritis caused by swelling of the lining of the joints), and ankylosing spondylitis (arthritis that mainly affects the spine). Indomethacin is also used to treat pain in the shoulder caused by bursitis (inflammation of a fluid-filled sac in the shoulder joint) and tendinitis (inflammation of the tissue that connects muscle to bone). Indomethacin immediate-release capsules and suspension (liquid) are also used to treat acute gouty arthritis (attacks of severe joint pain and swelling caused by a build-up of certain substances in the joints). Indomethacin is in a class of medications called NSAIDs. It works by stopping the body's production of a substance that causes pain, fever, and inflammation. (Sourced from: https://medlineplus.gov/druginfo/meds/a681027.html)
Mechanisms of Action: AKR1C3 Inhibitor,COX Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Rectal
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Iroko
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belgium, China, Czech Republic, Denmark, France, Greece, Hong Kong, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, Thailand, United States
Active Clinical Trial Count: 6
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Histiocytosis|Osteoarthritis|Pancreatitis|Shoulder Pain|Tennis Elbow|Tenosynovitis
Phase 2: Retinitis Pigmentosa
Phase 1: Male Breast Cancer|Triple Negative Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| HORA-PDE6B-001 | P2 |
Recruiting |
Retinitis Pigmentosa |
2029-11-07 |
2025-05-02 |
Treatments |
|
| StentvsNSAID | P3 |
Recruiting |
Pancreatitis |
2026-12-31 |
2025-02-13 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
|
| 042011 | P3 |
Not yet recruiting |
Histiocytosis |
2025-12-30 |
2025-05-02 |
Treatments |
|
| CTR20222093 | P3 |
Completed |
Tenosynovitis|Shoulder Pain|Tennis Elbow|Osteoarthritis |
2023-10-09 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
| ESBC | P1 |
Active, not recruiting |
Male Breast Cancer|Triple Negative Breast Cancer |
2019-05-13 |
23% |
2024-01-31 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| 2016-003568-38 | P3 |
Active, not recruiting |
Histiocytosis |
None |
2025-05-11 |
Treatments |